Iovance Biotherapeutics
IOVA
A$2.60
Share price
-2.86%
Change (1 day)
-76.00%
Change (1 year)
Categories
Iovance Biotherapeutics (IOVA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : A$0.30 Billion
According to Iovance Biotherapeutics 's latest financial reports the company's total liabilities are A$0.30 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Iovance Biotherapeutics - Total liabilities on balance sheet (from 2008 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | A$0.32 B | 11.93% |
| 2023-12-31 | A$0.28 B | 18.96% |
| 2022-12-31 | A$0.24 B | 12.47% |
| 2021-12-31 | A$0.21 B | 47.47% |
| 2020-12-31 | A$0.14 B | 123.15% |
| 2019-12-31 | A$65.24 M | 214.24% |
| 2018-12-31 | A$20.76 M | 63.88% |
| 2017-12-31 | A$12.67 M | 83.84% |
| 2016-12-31 | A$6.89 M | 208.03% |
| 2015-12-31 | A$2.23 M | 10.18% |
| 2014-12-31 | A$2.03 M | -20.2% |
| 2013-12-31 | A$2.54 M | -76.7% |
| 2012-12-31 | A$10.92 M | -16.12% |
| 2011-12-31 | A$13.01 M | 1507.15% |
| 2010-12-31 | A$0.81 M | 3047.54% |
| 2009-12-31 | A$0.02 M | 445.61% |
| 2008-12-31 | A$0 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 NRC Health
NRC | A$0.16 B | -46.95% | 🇺🇸 USA |
 Nymox Pharmaceutical NYMX | A$4.81 M | -98.42% | Bahamas |